Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
3
50%
Ph phase_4
1
17%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Other(1)

Detailed Status

Completed3
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 31 (16.7%)
Phase 41 (16.7%)

Trials by Status

completed350%
recruiting233%
unknown117%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_2

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

NCT05766800
recruitingphase_3

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

NCT06102395
completedphase_2

Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma

NCT02861690
completedphase_2

PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

NCT00016900
unknownphase_1

Clinical Study of Liposomal Paclitaxel in Chinese Patients

NCT00881101
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05766800Phase 2

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Recruiting
NCT06102395Phase 3

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Recruiting
NCT02861690Phase 2

Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma

Completed
NCT00016900Phase 2

PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

Completed
NCT00881101Phase 1

Clinical Study of Liposomal Paclitaxel in Chinese Patients

Unknown
NCT00606515Phase 4

Pharmacokinetics Study of Liposomal Paclitaxel in Humans

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6